Network meta-analysis of first-line immune checkpoint inhibitor therapy in advanced non-squamous non-small cell lung cancer patients with PD-L1 expression ≥ 50%

Network meta-analysis of first-line immune checkpoint inhibitor therapy in advanced non-squamous non-small cell lung cancer patients with PD-L1 expression ≥ 50%

Abstract Introduction The optimal first-line immunotherapy regimen for advanced non-squamous non-small cell lung cancer (NS-NSCLC) patients with programmed cell death ligand 1 (PD-L1) expression ≥ 50% remains unclear. Our aim is to determine the most effective treatment regimen through a network met...

Full description

Bibliographic Details
Main Authors: Wei Chen, Jiayi Chen, Lin Zhang, Sheng Cheng, Junxian Yu
Format: Article
Language:English
Published: BMC 2023-08-01
Series:BMC Cancer
Subjects:
Non-small cell lung cancer (NSCLC)
Immune checkpoint inhibitors (ICIs)
Programmed cell death-1 (PD-1)
Programmed cell death ligand-1 (PD-L1)
Network meta-analysis (NMA)
Online Access:https://doi.org/10.1186/s12885-023-11285-4

Internet

https://doi.org/10.1186/s12885-023-11285-4

Similar Items